{"paper_id":"e5fb53ce-c9dc-4dc0-82b8-50d7fb2b06f7","body_text":"We noted you are experiencing viewing problems\n-\nCheck with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.\n-\nCheck the following talk links to see which ones work correctly:\nAuto Mode\nHTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -\nNo luck yet? More tips for troubleshooting viewing issues\n-\nContact HST Support access@hstalks.com\n-\nPlease review our troubleshooting guide for tips and advice on resolving your viewing problems.\n-\nFor additional help, please don't hesitate to contact HST support access@hstalks.com\nWe hope you have enjoyed this limited-length demo\nThis is a limited length demo talk; you may\nlogin or\nreview methods of\nobtaining more access.\nPrintable Handouts\nNavigable Slide Index\n- Introduction\n- Disclosure\n- Talk outline\n- Current treatment for endometriosis\n- Pathophysiology\n- Proliferation\n- Anti-proliferation by progesterone\n- New progestin and SPRM\n- Anti-proliferation\n- Anti-proliferation mechanism (1)\n- Anti-proliferation mechanism (2)\n- Anti-recurrence\n- Summary (efficacy)\n- Summary (safety)\n- Immunology\n- Anti-immune escape by immunomodulator\n- Immunosuppression\n- Immune response in early endometriosis\n- Myeloid-derived suppressor cells (MDSCs)\n- T cell suppression\n- MDSC depletion\n- Molecular targets\n- Potential immuno-modulator\n- Adhesion\n- Anti-adhesion by herbal medicines\n- Common TCM formulas\n- Anti-endometriosis (herbal medicine)\n- Anti-endometriosis mechanism\n- Common individual herbs\n- Single herb & dose dependent effects\n- Angiogenesis\n- Anti-angiogenesis by green tea\n- Camellia sinensis\n- Tea polyphenols (catechins)\n- Biological properties\n- Anti-endometriosis (EGCG)\n- Anti-angiogenesis\n- Anti-angiogenesis mechanism\n- Prodrug of EGCG (pro-EGCG)\n- Efficacy of pro-EGCG\n- Molecular interactions\n- RCT of green tea for endometriosis\n- Summary\n- Thanks & contact info\nTopics Covered\n- Limitation of current treatment of endometriosis\n- Pathophysiology of endometriosis\n- Anti-proliferation of endometriosis by new progesterone\n- Anti-immune escape of endometriosis by immunomodulator targeting MDSCs\n- Anti-adhesion of endometriosis by herbal medicines and active components\n- Anti-angiogenesis of endometriosis by green tea and derivatives\n- Pharmacokinetics of biologics\nLinks\nCategories:\nTherapeutic Areas:\nTalk Citation\nWang, C.C.(. (2019, April 30). Research & development of new pharmaceuticals for treatment of endometriosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved June 11, 2026, from https://doi.org/10.69645/HPSA5071.Export Citation (RIS)\nPublication History\n- Published on April 30, 2019\nFinancial Disclosures\n- Professor Wang has a patented USPTO 9713603, licenced to Aptorum Therapeutics Ltd., and grants GRF 475012, HMRF 03141386, and ITF ITS/209/12\nResearch & development of new pharmaceuticals for treatment of endometriosis\nPublished on April 30, 2019\n49 min\nA selection of talks on Pharmaceutical Sciences\nTranscript\nPlease wait while the transcript is being prepared...\n0:00\nHi everybody. Thank you for your interest to my talk.\nMy name is Wang Chi Chiu Ronald,\nor you can call me Ronald.\nI am the Professor and Division Head of the Department\nof O&G in The Chinese University of Hong Kong.\nHere's where we all know,\nI'm happy to have a talk in Henry Stewart Talks.\nThe topic of my talk is \"R&D of New Pharmaceuticals for Treatment of Endometriosis\".\nFrom the topic, you can see that I'm going to cover the treatment\nof endometriosis and R&D of the new pharmaceuticals.\nSo, I hope you like it and find it very useful.\n0:41\nSo, first of all,\nI would like to disclose my collaborations,\nfunding, patents, and licenses.\nSo, you can see that I have several collaborations with Hiu Xu in\nHong Kong, McGill University and University of Oxford and also Havard University,\nColumbia University, and South Carolina.\nThe funding mainly is from Hong Kong.\nOne of them is RGC GRF,\nthe second is ITF Tier 3 ITS and the last one is the HMRF.\nSo, some of the contacts have a patents already.\nSo, you can identify the ID of the patents here.\nOne of the technology has been licensing through the pharmaceutical company.\n1:29\nSo, basically, the talk today will cover three areas.\nFirst of all, I will give you some background information,\nsuch as why we need the pharmaceuticals and\nhow we are going to design the new pharmaceuticals.\nSo we're going to talk about some physiology.\nIn the second part, we are going to introduce four main new pharmaceuticals that includes\nprogesterone, immunodulators, herbal medicine,\nand lastly I'm going to give you a summary.","source_license":"CC0","license_restricted":false}